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Summary. Modern trends in medical therapy of gout require the inclusion in the complex treatment of drugs that have a 
multifaceted spectrum of corrective properties, characterized by mildness, gradual action and have minimal side effects. 
Such requirements correspond to preparations of plant origin. The features of the therapeutic action of the combined plant 
urountiseptic drug " Uronephron " in the complex treatment of patients with gout have been studied. It was found that 
inclusion in the regimens of the treatment of gout "Uronoephron" favorably affects the articular, renal manifestations of the 
disease, reduces the level of hyperuricemia, reduces the frequent symptoms in patients with gout disease of the digestive 
system. Positive effect of treatment of patients with gout is due to diuretic, litholytic, antispasmodic, anti-inﬂ ammatory, 
antibacterial, antioxidant and general strengthening effect of the drug " Uronephron ".
Keywords: uroanteesiptics, «Uronephron», gout, polymorbidity, treatment.
Резюме: Сучасні тенденції медикаментозної терапії подагри вимагають включення в комплексне лікування лікарських 
засобів, які мають багатогранний спектр корегувальних властивостей, характеризуються м’якістю, поступовістю дії та 
володіють мінімальними побічними впливами. Таким вимогам відповідають препарати рослинного походження.
Досліджені особливості терапевтичної дії комбінованого рослинного уроантисептичного препарату «Уронефрон» в 
UDC 616 — 002.77
USING OF UROANTISEPTICSOF HERBAL ORIGIN AS A MEANS OF ADJUVANT 
THERAPY IN PATIENTS WITH GOUT
ЗАСТОСУВАННЯ УРОАНТИСЕПТИКІВ РОСЛИННОГО ПОХОДЖЕННЯ 
В ЯКОСТІ ЗАСОБІВ АД’ЮВАНТНОЇ ТЕРАПІЇ У ХВОРИХ НА ПОДАГРУ
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Introduction.Over the past decade the prevalence of gout has in-
creased signiﬁ cantly, due both to an increase in alcohol, foods rich in 
purines, and higher levels of diagnosis [4, p. 4-6]. A large proportion of 
the growth in the incidence of gout belongs uncontrolled taking of medi-
cations that induce the development of gout: diuretics, methylxanthine, 
Riboxinum, adenosine triphosphate ( ATP), even low doses of aspi-
rin. In recent years proved that some widely used food additives like 
MSG, in foods provoke breach of purine metabolism and promote the 
development of gout. Signiﬁ cant disability due to these nosology and 
economic costs of their treatment determine the relevance of studying 
of combined pathology [1, p.4-5; 5, p.16].
Signiﬁ cant difﬁ culties in the treatment of gout are often caused by 
late detection and its almost natural premorbid background that signiﬁ -
cantly obstruct realization of long-term (lifetime) use of a main medica-
ment of allopurinol [6, p.111-116].  Modern trends in medical therapy, 
especially in cases of mixed pathology demanding, need inclusion in 
treatment medications that have versatile range of corrective proper-
ties ,and are  characterized by soft, gradual steps don’t have or have 
minimal side effects. Such requirements correspond to medicaments of 
herbal origin [2, p.32−34; 3, p.258-262].
The goal of the study was to investigate the characteristics of the 
therapeutic effects of combined plant uroantiseptic medicament "Uro-
nephron" which includes liquid extract obtained by extraction of 45% 
ethanol with onionskin, Goldenrod herb, the roots of lovage, birch 
leaves, grasses, horsetail, roots of couch grass, seeds of fenugreek, 
parsley root, in the complex treatment of patients with gout [7, 632].
Material and methods. The research was conducted during the 
year in the rheumatological department of the city hospital №3 in Cher-
nivtsi. 25 patients with chronic gout were inquiring during the exacerba-
tion. The diagnosis of gout was put according to Wallace’s criteria and 
co-authors and recommendations of Ukrainian Association of Rheuma-
tology and MOH Ukraine number 676 of 12.10.2006r. Fromsection 13 
"Rheumatology". The diagnosis of gout based on complaints, carefully 
assembled medical history, physical examination results, X-ray data, 
ultrasonography examination parameters and biochemical studies of 
blood, urine. X-ray examinations of affected joints were done by stan-
dard methods. In all patients were noticed ultrasonic signs of urine acid 
diathesis or urinary-stone disease.  All patients were male, in age from 
37 to 72 years with duration of history of the disease from 5 to 17 years.
All patients received standard basic therapy in acute period, pa-
tients received according to the Protocol MOH Ukraine number 675 of 
chapter 13 "Rheumatology" in 2010, namely  primarily NSAIDs (Nime-
sulidum or Movalis), local compresses of Dimethoxide with a solution 
of NSAIDs or ointment "Remisid " and since improved - from 10-12 day 
was used  allopurinol in  low (100 mg / day) doses, gradually increas-
ing to 300 mg / day by the end of the third week and transferred to 
outpatient treatment allopurinol (comparison group). 15 patients (study 
group) - additionally were designated "Uronephron" 1 teaspoon 3-4 
times a day during 1 month. Criteria of efﬁ ciency: clinical, laboratory 
and biochemical (blood, urine - the dynamics of uric acid and urinary 
sediment).
Research results. The results of the treatment of patients with gout 
in the main group were respectively better than the comparison group. 
Observations have found that at a stationary stage of treatment in pa-
tients of group 2-3 days started earlier and was accelerated regression 
of a painful joint syndrome, allowing a 7-8 day to reduce at half the daily 
dose of NSAIDs and in 1-2 days earlier it cancels. 
It should be noted that there is a direct effect of "Uronephron" on 
any manifestations of gastro- or cholecystopancreatopathy: at the time 
of discharge from the hospital, special complaints from these systems 
did not show patients. This situation allowed after the 20th day of ap-
plication to cancel in 12 patients proton pump-inhibitors, and in others 
- to go on a single dose administration in a day. Also, the effect of these 
agents on the clinical manifestations of osteoarthritis was noticeable 
in the form of a decrease in articular pain syndrome and crunch in the 
affected joints.
Determined that in patients of the main group was noticed in-
creased frequency urination (quantitatively and qualitatively), turbidity 
of urine excretion of uric acid. From day 7-10 frequency of urinary close 
to normal, patients noted a rise of transparency urine with episodes of 
its turbidity, reducing discomfort in the back. It is important symptoms 
of accompanying cholecystohepatopathy, irritation bowel syndrome 
has a tenency to of regression clearer than in the comparison group 
of patients.
According to ultrasound data, before constipation of the kidneys, 
convincing evidence of kidney stones was detected in 20.0% patients, 
and in 71.43% - marked diarrheal urinary events, were 34, 28% - cor-
tical-medullary differentiation was found to be a possible proof of in-
terstitial lesion of kidney parenchyma. No pathological changes were 
detected in only 3 patients with the ﬁ rst diagnosis and under 42 years 
of age. After 2 weeks of use "Uronephron"the probable changes in the 
ultrasound examination were not detected.
After 2 weeks of use "Uronephron" dynamics of reducing uric acid 
in the blood was better than in the comparison group, but the differ-
ence was not probable. In patients in both research groups until the 
end of inpatient treatment was probable to improve parameters: white 
blood cells, erythrocyte sedimentation rate, C-reactive protein, how-
ever differences, between groups were not found. These phenomena 
can be explained by factors components "Uronephron": extracts of 
couch grass roots, lovage, parsley, Goldenrod herb, horsetail, sina-
pism, seeds of fenugreek, onion peel, birch leaves. Their combined 
effect makes diuretic, antispasmodic, anti-inﬂ ammatory, antibacterial, 
antioxidant and general ﬁ rming action [8, p.533]. It was important also 
detecting the probable reduction in creatinine blood on the 20th day 
by using “Uronephron” that may be probable evidence by improve him 
kidney function.
We researched the concentration in the blood of the reaction prod-
ucts uricacid content of glutathione in the blood, activity of catalase, 
glutathione peroxidase.As a result of research discovered a signiﬁ cant 
increase in the concentration of reduced glutathione during treatment 
in patients who additionally received “Uronephron”. They had contents 
of reduced glutathione after treatment higher by 26,1% (р<0,05) in 
compare with contents before treatment. The trend to reduced activity 
of glutathione peroxidase observed during treatment in both groups of 
patients, but it was not credible.Blood catalase activity signiﬁ cantly in-
creased after treatment in patients who took “Uronephron” on average 
комплексному лікуванні хворих на подагру. Було встановлено, що включення в схеми лікування подагри «Уронефрону» 
сприятливо впливає на суглобові, ниркові прояви хвороби, знижує рівень гіперурикемії, зменшує симптоматику частих 
у пацієнтів із подагрою уражень системи травлення. Позитивний ефект лікування хворих на подагру зумовлений 
діуретичною, літолітичною, спазмолітичною, протизапальною, антибактеріальною, антиоксидантною та загально 
зміцнювальною дією препарату «Уронефрон».
Ключові слова: уроантисептики, «Уронефрон», подагра, поліморбідність, лікування.
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by 20,4% (p <0,05) in compare with that before treatment, in patients 
of the group of compare – by 13,8% (p <0,05).After treatment we could 
see decrease of concentration of reaction products of uricacid in pa-
tients of both group, more reduction of their content noted in patients, 
whom to complex treatment was included “Uronephron”.
In patients who took “Uronephron”, excretion of uric acid was in-
creased by the kidneys. The concentration of uric acid in urine increased 
by 29,6%, with a maximum value of 2.00 and 14.00.Standard treatment led 
to a decrease in urinary acid excretion by the kidneys by only 7.9%, and the 
daily rhythm was characterized by maximum values at 10.00 and at 14.00.
Particularly important were signiﬁ cantly lower activity of alanine 
aminotransferase, aspartate aminotransferase, lactate dehydrogenase, 
alkaline phosphatase, gammaglutamyltransferase and of total bilirubin 
in patients of the main group, which is strong evidence of its inherent 
hepatoprotective properties. Noteworthy is reduction, though not prob-
able, on the 20th day of treatment, levels of cholesterol, triglycerides and 
blood glucose, which give reason to investigate the cholesterol-lowering 
and hypoglycemic effects "Uronephron" in the longer their application.
Some (False) positive changes in calcium and phosphorus levels 
in serum may indicate a favorable effect "Uronefron" in the calcium-
phosphorus metabolism, which is important in the study of patients due 
to the fact that with age by them develop osteoarthritis, osteoporosis.
Cannot stay out of our attention, improving of iron in the blood se-
rum, in patients of the main group: it probably grew (although within the 
reference values of normal), while patients in the comparison even de-
creased, which may have the result of the negative impact nonsteroidal 
anti-inﬂ ammatory medicaments and of allopurinol.
Interestingly, blood glucose levels are more signiﬁ cant than in the 
comparison group. Although this decrease compared to baseline was 
unlikely, it is possible that hypoglycemic properties may be detected in 
longer-term use of "Uronefron".
All patients rated tolerability of "Uronephron" as excellent and good.
Conclusions :
1. Herbal complex uroantiseptic medicament "Uronephron" is a valuable adjuvant tool in the treatment of patients with gout 
and has positive effect on joints, the renal manifestations of the disease, reduces the level of hyperuricimy. Also, the effect 
of these "Uronephron"on the clinical manifestations of osteoarthritis was noticeable in the form of a decrease in articular 
pain syndrome and crunch in the affected joints.
2. Using  of "Uronephron" reduces symptoms in patients with frequent gout lesions of the digestive system, Since the drug 
has hepatoprotective and hypocholesterolemic properties.
3. The "Uronefron"positive changes in the calcium-phosphorus metabolism, which is very important for older patients who 
suffer from osteoarthritis and osteoporosis.
4. The positive effect of the treatment of gout are caused by diuretic, spasmolytic, anti-inﬂ ammatory, antibacterial, antioxi-
dant and general strengthening effect of the medicament "Uronephron."
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